Skip to main content

Table 2 Key base case cost-effectiveness model inputs

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Input parameters

Base case value

References

Vaccination

  

Duration of vaccine protection

Lifetime

Assumption

Age at Vaccination (years)

12

Assumption

Vaccine Coverage

100%

Assumption

Efficacy: HPV-16/18 (both vaccines)

98.0%

[26, 46–50]

HPV-16/18 AS04-adjuvanted Vaccine

  

Efficacy: Non-vaccine oncogenic HPV types

  

   CIN1

47.7% (95% CI: 28.9%, 61.9%)

[51]

   CIN2+

68.4% (95% CI: 45.7%, 82.4%)

[25]

HPV-6/11/16/18 vaccine Efficacy: Non-vaccine oncogenic HPV types

 

[27]

   CIN1

23.4% (95% CI: 7.8%, 36.4%)

 

   CIN2+

32.5% (95% CI: 6.0%, 51.9%)

 

HPV-6/11/16/18 Vaccine Efficacy: HPV 6/11

98.0%

[50]

Screening

  

Screening Coverage

 

[52]

   Age Range

18 to 69 years

 

   Regular (once/ 3 years)

70%

 

   Irregular (ages 25, 40, 50)

18%

 

   Never

12%

 

CIN1 detected (sensitivity)

42%

[44, 52, 53]

CIN2/3 detected (sensitivity)

55%

[44, 52, 53]

% Positive pap Smear

5%

[44, 52, 53]

Cost (2006 CAD)

  

HPV-16/18 AS04-adjuvanted vaccine Cost (per dose)

$110.97

Assumption

HPV-6/11/16/18 vaccine Cost (per dose)

$110.97

Assumption

Genital Warts treatment (per episode)

$207.00

[44]

Cytology Test

$57.00

[30, 33, 54]

Colposcopy and biopsy

$150.00

[30, 33, 54]

CIN1 treatment and follow-up*

$843.00

[30, 33, 54]

CIN2/3 treatment and follow-up*

$1 414.00

[30, 33, 54]

Cervical cancer stage 1

$11 915.00

[30, 33, 54]

Cervical cancer stage 2

$18 851.00

[30, 33, 54]

Cervical cancer stage 3

$18 851.00

[30, 33, 54]

Cervical cancer stage 4

$25 759.00

[30, 33, 54]

Utility

  

No HPV, HPV Infection

1, 1

 

CIN1 detected

0.987

[55–58]

CIN2/3 detected

0.991

[55–58]

Cancer treated

0.727

[55–58]

Cancer cured

0.938

[55–58]

Genital Warts

0.980†

[59]

  1. * Cost calculated assuming that 50% of CIN1 and 100% of CIN2/3 are treated. Follow-up after CIN1/2/3 assumed to include 2 additional cytology tests and colposcopies for all patients.
  2. † Genital warts assumed to cause a decrement of 0.8 in utility across 3 months.